CEL-SCI (NYSE:CVM) Upgraded at StockNews.com

StockNews.com upgraded shares of CEL-SCI (NYSE:CVM) from a sell rating to a hold rating in a research note released on Tuesday.

CEL-SCI Price Performance

Shares of NYSE CVM opened at $0.70 on Tuesday. The stock’s 50-day simple moving average is $0.99 and its 200-day simple moving average is $1.16. The firm has a market capitalization of $44.71 million, a PE ratio of -1.21 and a beta of 0.69. CEL-SCI has a fifty-two week low of $0.68 and a fifty-two week high of $3.23. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64.

CEL-SCI (NYSE:CVM) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, equities research analysts forecast that CEL-SCI will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On CEL-SCI

A number of institutional investors and hedge funds have recently bought and sold shares of CVM. Vanguard Group Inc. increased its position in shares of CEL-SCI by 5.5% during the first quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock worth $4,189,000 after purchasing an additional 113,703 shares in the last quarter. Renaissance Technologies LLC grew its stake in CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after buying an additional 40,000 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in CEL-SCI by 140.9% during the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after buying an additional 80,001 shares during the period. Cutter & CO Brokerage Inc. boosted its holdings in shares of CEL-SCI by 29.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after acquiring an additional 24,634 shares during the period. Finally, Black Diamond Financial LLC grew its position in shares of CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the last quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.